AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Mitochondria Targeting Kills Cancer Cell without Acquired Drug Resistance

Technology Benefits

Achieves high selectivity in mitochondrial targeting of cancer cell;The first example to integrate subcellular targeting and spatial control of the assemblies of non-specific cytotoxic agents by EISA as a promising molecular process for selectively killing cancer cells;A new way for developing efficient nanomedicine without inducing acquired drug resistance.

Detailed Technology Description

The invention introduces a novel method to target organelles by modulating the redox potential of mitochondria and ultimately serve as a therapeutic approach to cancer and other immune-deficient disease. This bioinspired system is achieved by utilizing enzyme-instructed self-assembly (EISA) to kill cancer cells that minimizes acquired drug resistance.

Countries

United States

Application No.

PCT/US2018/012359

Country/Region

USA

For more information, please click Here